Medlab Presents at APP 2021

Australian Pharmacy Professional Conference and Trade Exhibit 2021

Date of Event:   2021-05-20 - 2021-05-23
Location:  2684 Gold Coast Hwy, Broadbeach QLD 4218, Australia

Medlab is proud to present at the Australian Pharmacy Professional Conference and Trade Exhibit (APP) 2021, between the 20th and 23rd May 2021

Visit us at our booth 26 and 27

Location - Gold Coast Convention and Exhibition Centre



Cannabis-based medicine - results of a clinical trial in cancer pain

This session will examine the results of a completed clinical study investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. The bioavailability of Medlab’s cannabis-based medicine has shown superior PK compared to nabiximols (the only cannabis-based medicine approved by the TGA) when used in the management of cancer pain. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.

Looking forward to seeing you on Saturday 22 May at 9:15 am.


  • Meeting Rooms 5-7
  • Gold Coast Convention and Exhibition Centre

Time - 9:15am - 9:45am

Dates  - 20-23rd May 2021


Professor Luis Vitetta, Director of Medical Research at Medlab
Director of Medical Research
Professor Luis Vitetta

Luis is Director of Medical Research at Medlab Clinical and Adjunct Professor at the University of Sydney, Sydney Medical School. Luis has an extensive depth of knowledge of the science behind effective probiotics and biologic medicines. His focus on clinical research and its relevance to commercialisation informs Medlab's product portfolio.

After many years of educating clinicians, pharmacists, undergraduate and postgraduate students, Luis is in a strong position to advance Medlab's clinical research activities and drug innovation projects to the clinical practitioner community.


Tell us what you think login to share your thoughts.